Literature DB >> 23256165

Guideline funding and conflicts of interest: article 4 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.

Elizabeth A Boyd, Elie A Akl, Michael Baumann, J Randall Curtis, Marilyn J Field, Roman Jaeschke, Molly Osborne, Holger J Schünemann.   

Abstract

INTRODUCTION: Professional societies, like many other organizations around the world, have recognized the need to use more rigorous processes to ensure that healthcare recommendations are informed by the best available research evidence. This is the fourth of a series of 14 articles prepared to advise guideline developers in respiratory and other disease. It focuses on commercial funding of guidelines and managing conflict of interest effectively in the context of guidelines.
METHODS: In this review, we addressed the following topics and questions. (1) How are clinical practice guidelines funded? (2) What are the risks associated with commercial sponsorship of guidelines? (3) What relationships should guideline committee members be required to disclose? (4) What is the most efficient way to obtain complete and accurate disclosures? (5) How should disclosures be publicly shared? (6) When do relationships require management? (7) How should individual conflicts of interest be managed? (8) How could conflict of interest policies be enforced? The literature review included a search of PubMed and other databases for existing systematic reviews and relevant methodological research. Our conclusions are based on available evidence, consideration of what guideline developers are doing, and workshop discussions. RESULTS AND DISCUSSION: Professional societies often depend on industry funding to support clinical practice guideline development. In addition, members of guideline committees frequently have financial relationships with commercial entities, are invested in their intellectual work, or have conflicts related to clinical revenue streams. No systematic reviews or other rigorous evidence regarding best practices for funding models, disclosure mechanisms, management strategies, or enforcement presently exist, but the panel drew several conclusions that could improve transparency and process.

Mesh:

Year:  2012        PMID: 23256165     DOI: 10.1513/pats.201208-057ST

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  12 in total

Review 1.  Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases.

Authors:  Holger J Schünemann
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

2.  Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise.

Authors:  Holger J Schünemann; Wojtek Wiercioch; Itziar Etxeandia; Maicon Falavigna; Nancy Santesso; Reem Mustafa; Matthew Ventresca; Romina Brignardello-Petersen; Kaja-Triin Laisaar; Sérgio Kowalski; Tejan Baldeh; Yuan Zhang; Ulla Raid; Ignacio Neumann; Susan L Norris; Judith Thornton; Robin Harbour; Shaun Treweek; Gordon Guyatt; Pablo Alonso-Coello; Marge Reinap; Jan Brozek; Andrew Oxman; Elie A Akl
Journal:  CMAJ       Date:  2013-12-16       Impact factor: 8.262

3.  Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study.

Authors:  Paul Campsall; Kate Colizza; Sharon Straus; Henry T Stelfox
Journal:  PLoS Med       Date:  2016-05-31       Impact factor: 11.069

4.  Requirements of Clinical Journals for Authors' Disclosure of Financial and Non-Financial Conflicts of Interest: A Cross Sectional Study.

Authors:  Khaled Shawwa; Romy Kallas; Serge Koujanian; Arnav Agarwal; Ignacio Neumann; Paul Alexander; Kari A O Tikkinen; Gordon Guyatt; Elie A Akl
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

5.  Methodological quality of systematic reviews referenced in clinical practice guidelines for the treatment of opioid use disorder.

Authors:  Andrew Ross; Justin Rankin; Jason Beaman; Kelly Murray; Philip Sinnett; Ross Riddle; Jordan Haskins; Matt Vassar
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

6.  Managing conflicts of interest in the development of health guidelines.

Authors:  Gregory Traversy; Lianne Barnieh; Elie A Akl; G Michael Allan; Melissa Brouwers; Isabelle Ganache; Quinn Grundy; Gordon H Guyatt; Diane Kelsall; Gillian Leng; Ainsley Moore; Navindra Persaud; Holger J Schünemann; Sharon Straus; Brett D Thombs; Rachel Rodin; Marcello Tonelli
Journal:  CMAJ       Date:  2021-01-11       Impact factor: 8.262

7. 

Authors:  Gregory Traversy; Lianne Barnieh; Elie A Akl; G Michael Allan; Melissa Brouwers; Isabelle Ganache; Quinn Grundy; Gordon H Guyatt; Diane Kelsall; Gillian Leng; Ainsley Moore; Navindra Persaud; Holger J Schünemann; Sharon Straus; Brett D Thombs; Rachel Rodin; Marcello Tonelli
Journal:  CMAJ       Date:  2021-03-01       Impact factor: 8.262

Review 8.  Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Authors:  Marc Miravitlles; Nicolas Roche; João Cardoso; David Halpin; Zaurbek Aisanov; Hannu Kankaanranta; Vladimir Kobližek; Paweł Śliwiński; Leif Bjermer; Michael Tamm; Francesco Blasi; Claus F Vogelmeier
Journal:  Respir Res       Date:  2018-01-18

9.  Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation.

Authors:  Viviane Karoline da Silva Carvalho; Maria Sharmila Alina de Sousa; Jorge Otávio Maia Barreto; Everton Nunes da Silva
Journal:  BMC Health Serv Res       Date:  2019-10-28       Impact factor: 2.655

10.  Examining the sources of evidence in e-cigarette policy recommendations: A citation network analysis of international public health recommendations.

Authors:  Marissa J Smith; Andrew J Baxter; Kathryn Skivington; Mark McCann; Shona Hilton; Srinivasa Vittal Katikireddi
Journal:  PLoS One       Date:  2021-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.